Vizient serves more than 65% of the nation’s acute care providers, including 97% of academic medical centers

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced the availability of the Vibativ (telavancin) 4-Vial Starter Pak through a new contract with Vizient, the nation’s largest provider-driven healthcare performance improvement company.

Vizient serves more than 65% of the nation’s acute care providers, including 97% of academic medical centers and 35% of the non-acute market. Through this agreement, Vizient members now have increased access to Vibativ’s new 4-vial configuration, which supports flexible treatment initiation in both inpatient and outpatient settings for this potentially life-saving therapy.

“We’re pleased to expand availability of the new Vibativ 4-Vial Starter Pak for Vizient-contracted providers, supporting the cost-efficient delivery of our potent antibiotic in hospitals, infusion centers and outpatient centers nationwide,” said A.J. Kazimi, CEO of Cumberland Pharmaceuticals.

Vibativ is an FDA-approved injectable antibiotic indicated for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), as well as complicated skin and skin structure infections (cSSSI) caused by Gram-positive pathogens, including MRSA.

Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com

Source- PR Newswire